trending Market Intelligence /marketintelligence/en/news-insights/trending/O5Oeeu5a2ddJBMiqScg28Q2 content esgSubNav
In This List

HRA Capital to help raise funds for Nascent Biotech's brain cancer drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


HRA Capital to help raise funds for Nascent Biotech's brain cancer drug

Nascent Biotech Inc. has engaged HRA Capital to help raise capital to fund the continual development of Pritumumab, a drug to treat brain cancer, through its phase 1 and phase 2 clinical trials.